Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

and in those undergoing major orthopedic surgery, treatment and secondary prevention of VTE, and acute coronary syndromes (ACS).

About Atrial Fibrillation

Atrial fibrillation (AF) is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. In atrial fibrillation, some blood inside the atria may stagnate, and clots may form. If a piece of the clot breaks off and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC guidelines for the management of atrial fibrillation, patients with atrial fibrillation have a two- to seven-fold increased risk of stroke and also have an increased risk of death and cardiovascular complications, including myocardial infarction.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development, addressing the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... of scientific research products, recently opened an online ... comprehensive cell culture product lines developed and manufactured ... its online store include Biological Industries’ Nutristem® serum-free, ... and human embryonic stem cell (hESC) culture. ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... Arginine vasopressin (AVP) receptor antagonist now approved in single-use ... ... 22 Astellas Pharma US, Inc. today,announced that the U.S. ... of Vaprisol: Vaprisol(R) (conivaptan hydrochloride,injection) Premixed in 5% Dextrose. Discovered ...
... November 18, 2008, WITTEN, Germany, October 22 ... fiscal year,ended June 30, 2008, on October 21. According ... SEC the company yielded sales of its cosmetics and ... a decrease,of 44% as compared with sales revenues of ...
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... that it will present at three upcoming investor conferences:, ... the Hyatt Regency in La,Jolla, Calif. on Monday, October ... -- Oppenheimer,s 19th Annual Healthcare Conference to be ...
Cached Biology Technology:FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses 2Halozyme Therapeutics to Present at Upcoming Investor Conferences 2
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... The U.S. Food and Drug Administration (FDA) granted market ... bionic eye to be approved for patients in the ... with support from the National Science Foundation (NSF). ... transmits images from a small, eye-glass-mounted camera wirelessly to ...
... be an early step toward new treatments for people with ... probiotic supplement can help male mice produce healthier bones. ... researchers report in the Journal of Cellular Physiology . ... bone loss, though it,s unclear exactly why," said lead author ...
... that cold-blooded animals, such as worms, flies and fish ... known exactly why. , Researchers at the University of ... that promotes longevity of roundworms in cold environmentsand this ... , "This raises the intriguing possibility that exposure to ...
Cached Biology News:Artificial retina receives FDA approval 2Artificial retina receives FDA approval 3Artificial retina receives FDA approval 4Artificial retina receives FDA approval 5Building healthy bones takes guts 2Stay cool and live longer? 2
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: